WO2008094065A1 - MÉTHODE ET AGENT À BASE DE SOUCHES D'Enterococcus faecium M (VKPM B-3490) ET D'Enterococcus faecium M-3185 (VKPM B-3491) SERVANT AU TRAITEMENT D'HÉPATITES VIRALES - Google Patents

MÉTHODE ET AGENT À BASE DE SOUCHES D'Enterococcus faecium M (VKPM B-3490) ET D'Enterococcus faecium M-3185 (VKPM B-3491) SERVANT AU TRAITEMENT D'HÉPATITES VIRALES Download PDF

Info

Publication number
WO2008094065A1
WO2008094065A1 PCT/RU2007/000051 RU2007000051W WO2008094065A1 WO 2008094065 A1 WO2008094065 A1 WO 2008094065A1 RU 2007000051 W RU2007000051 W RU 2007000051W WO 2008094065 A1 WO2008094065 A1 WO 2008094065A1
Authority
WO
WIPO (PCT)
Prior art keywords
vkpm
viral hepatitis
strain
epterosossi
strains
Prior art date
Application number
PCT/RU2007/000051
Other languages
English (en)
Russian (ru)
Inventor
Alexei Nikolaevich Parfenov
Igor Gennadievich Bakulin
Vladislav Grigorievich Novozhenov
Igor Borisovich Ushakov
Irina Nikolaevna Khlopova
Original Assignee
Alexei Nikolaevich Parfenov
Igor Gennadievich Bakulin
Novozhenov Vladislav Grigoriev
Igor Borisovich Ushakov
Irina Nikolaevna Khlopova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexei Nikolaevich Parfenov, Igor Gennadievich Bakulin, Novozhenov Vladislav Grigoriev, Igor Borisovich Ushakov, Irina Nikolaevna Khlopova filed Critical Alexei Nikolaevich Parfenov
Priority to PCT/RU2007/000051 priority Critical patent/WO2008094065A1/fr
Publication of WO2008094065A1 publication Critical patent/WO2008094065A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • VKPM B-3490 Enterosossiens faesit M
  • VKPM B-3491 Epterosossiis faesiit M-3185
  • the invention relates to the field of medicine and biotechnology, in particular to the use of strains of Epterosossi faesi M VKPM (B-3490) and Epterosossi faesi M-3185 (VKPM B-3491), compositions, agents and preparations based on them for the treatment of viral hepatitis.
  • the disadvantages of the known methods include: limitation in some cases of their use, including due to contraindications (the presence of anemia, leuko- and thrombocytopenia, concomitant diseases, etc.), the development of various complications (leuko-, neutro- and thrombocytopenia, anemia), which often requires discontinuation of drugs, low efficiency (chronic hepatitis B, patients with chronic hepatitis C with 1 genotype of HCV RNA, etc.)
  • the present invention provides for the use of strains of Epterosossis faesiit M (VKPM B-3490) and Epterosossiis faesiit M-3185 (VKPM B-3491), the composition, means and preparation "Bilactin" based on them for the treatment of viral hepatitis.
  • the invention also provides a method of treating viral hepatitis.
  • the liver being the largest gland of the animal’s body, participates in the processes of digestion, metabolism (carrying out key moments in carbohydrate, protein and fat metabolism), blood circulation, and performs specific protective, neutralizing, enzymatic and excretory functions aimed at maintaining a constant environment of the body.
  • Hepatotropic viruses can lead to toxic damage to liver cells (hepatocytes), impaired liver function, to the development of fibrotic changes in liver tissue with subsequent transition to liver cirrhosis, hepatocellular carcinoma.
  • the present invention provides that, in a regimen for treating viral hepatitis, patients are prescribed an inside agent for treating viral hepatitis, including the effective amount of the strain of Epterosossis faesite M (VKPM B-3490) and / or the amount of the strain of Epterosossis faecitum M-3185 (VKPM B-3491) and a pharmaceutically acceptable carrier or preparation containing the strains of Epterosossi faesit M (VKPM-34 and VKPM B-3490) or Epterosossia cont M-3185 (VKPM B-3491) once or three times a day for 10-180 days.
  • an inside agent for treating viral hepatitis including the effective amount of the strain of Epterosossis faesite M (VKPM B-3490) and / or the amount of the strain of Epterosossis faecitum M-3185 (V
  • Bilactin strains, composition, agent or drug made on their basis in the treatment of patients with acute viral hepatitis A, B and C during the icteric period provides favorable dynamics of clinical manifestations, leading to a reduction in the duration of intoxication (by 2-8 days compared with the comparison group), more quickly normalizing the general condition of patients, increasing their activity, which contributes to a significant improvement in treatment outcomes and improving the quality of life of patients.
  • An agent for treating viral hepatitis includes an effective amount of a strain of Epterosossi faesit M (VKPM B-3490) and / or an amount of a strain of Epterosossi faeciit M-3185 (VKPM B-3491) and a pharmaceutically acceptable carrier.
  • Epiterososs faesite M freeze-dried microbial mass up to 60%
  • Epotherososs faesite M-3185 (VKPM B-3491) residual soluble solids up to 20% of the growing medium
  • Bilactin In order to study the clinical efficacy of Bilactin, a study was conducted on two groups of male patients (83 people) aged 18 to 58 years.
  • the first group included patients (38 people) who, in addition to basic therapy, took Bilactin.
  • the drug was prescribed as a course for 14-30 days while in the hospital for OD g (1 capsule) 3 times a day.
  • "Bilactin" was prescribed by the research doctor immediately after the diagnosis of acute viral hepatitis.
  • the second group included patients (45 people) who received only basic therapy and made up the comparison group.
  • Concomitant diseases were identified in a number of patients. In the test group, concomitant pathology was established in 5 patients: hypertension in two, in three - chronic cholecystopancreatitis. In the comparison group, concomitant diseases were observed in 7 patients: hypertension - in 2, chronic cholecystopancreatitis - in 4 and peptic ulcer of the duodenum - in one.
  • test and control groups were comparable in terms of age composition, disease severity, concomitant diseases, quality and composition of basic therapy for basic therapy.
  • patients of the test group received 0.1 g of Bilactin. 3 times a day, after meals.
  • Patient comparison groups received only basic therapy. Treatment with Bilactin was prescribed no later than 5 days from the onset of the icteric period.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne l'utilisation de souches d'Enterococcus faecium M (VKPM B-3490) et d'Enterococcus faecium M-3185 (VKPM B-3491) et d'une composition, d'un agent et d'une préparation de 'Bilactine' à base de ces souches pour le traitement d'hépatites virales. Cette invention concerne également des méthodes de traitement d'hépatites virales aiguës.
PCT/RU2007/000051 2007-02-02 2007-02-02 MÉTHODE ET AGENT À BASE DE SOUCHES D'Enterococcus faecium M (VKPM B-3490) ET D'Enterococcus faecium M-3185 (VKPM B-3491) SERVANT AU TRAITEMENT D'HÉPATITES VIRALES WO2008094065A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/RU2007/000051 WO2008094065A1 (fr) 2007-02-02 2007-02-02 MÉTHODE ET AGENT À BASE DE SOUCHES D'Enterococcus faecium M (VKPM B-3490) ET D'Enterococcus faecium M-3185 (VKPM B-3491) SERVANT AU TRAITEMENT D'HÉPATITES VIRALES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2007/000051 WO2008094065A1 (fr) 2007-02-02 2007-02-02 MÉTHODE ET AGENT À BASE DE SOUCHES D'Enterococcus faecium M (VKPM B-3490) ET D'Enterococcus faecium M-3185 (VKPM B-3491) SERVANT AU TRAITEMENT D'HÉPATITES VIRALES

Publications (1)

Publication Number Publication Date
WO2008094065A1 true WO2008094065A1 (fr) 2008-08-07

Family

ID=39674285

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2007/000051 WO2008094065A1 (fr) 2007-02-02 2007-02-02 MÉTHODE ET AGENT À BASE DE SOUCHES D'Enterococcus faecium M (VKPM B-3490) ET D'Enterococcus faecium M-3185 (VKPM B-3491) SERVANT AU TRAITEMENT D'HÉPATITES VIRALES

Country Status (1)

Country Link
WO (1) WO2008094065A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004553A1 (fr) * 1995-07-15 1997-02-06 Philips Electronics N.V. Manipulation de paquets de donnees
WO2004005492A2 (fr) * 2002-07-03 2004-01-15 Galina Gennadievna Alekhina Composition probiotique a base d'une souche d'enterocoques pour moyens de traitement et de prevention et procede de fabrication correspondant
KR100468522B1 (ko) * 2004-10-12 2005-01-31 주식회사 프로바이오닉 코로나바이러스와 돼지 써코바이러스 2형의 생육을 억제하는 신규한 내산성 프로바이오틱 엔테로코커스훼시움 프로바이오-63
RU2006109107A (ru) * 2003-08-26 2006-08-10 Общество С Ограниченной Ответственностью "Алэф-Фарма" (Ru) Применение штаммов enterococcus faecium для лечения печеночной недостаточности, для регенерации и интенсификации метаболизма в печени

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004553A1 (fr) * 1995-07-15 1997-02-06 Philips Electronics N.V. Manipulation de paquets de donnees
WO2004005492A2 (fr) * 2002-07-03 2004-01-15 Galina Gennadievna Alekhina Composition probiotique a base d'une souche d'enterocoques pour moyens de traitement et de prevention et procede de fabrication correspondant
RU2006109107A (ru) * 2003-08-26 2006-08-10 Общество С Ограниченной Ответственностью "Алэф-Фарма" (Ru) Применение штаммов enterococcus faecium для лечения печеночной недостаточности, для регенерации и интенсификации метаболизма в печени
KR100468522B1 (ko) * 2004-10-12 2005-01-31 주식회사 프로바이오닉 코로나바이러스와 돼지 써코바이러스 2형의 생육을 억제하는 신규한 내산성 프로바이오틱 엔테로코커스훼시움 프로바이오-63

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GRACHEVA N.M.: "Effektivnost lecheniya ostrykh kishechnykh infektsy, khronicheskikh boleznei zheludochno-kishechogo trakta i virusnogo geptita B bolshimi dozami otechestvennogo bifidumbakterina forte", VOENNO-MEDITSINSYK ZHURNAL, vol. 320, no. 5, May 1999 (1999-05-01), pages 51 - 57 *

Similar Documents

Publication Publication Date Title
Chotmongkol et al. Treatment of eosinophilic meningitis with a combination of albendazole and corticosteroid
Wang et al. Research progress in the treatment of complications and sequelae of COVID-19
TW201026317A (en) Use of cycloartane compounds for treating arthritis
Hüseyin et al. Cyclosporin treatment of anal and perianal lesions associated with Crohn's disease
Bando et al. Effective Treatment for Type 2 Diabetes (T2D) by Imeglimin (Twymeeg) and Vildagliptin/Metformin (Equmet)
US20050137265A1 (en) Rapidly dissolving metoclopramide solid oral dosage and method thereof
RU2445107C2 (ru) СПОСОБ И СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ГЕПАТИТОВ НА ОСНОВЕ ШТАММОВ Enterococcus faecium M (ВКПМ В-3490) И Enterococcus faecium М-3185 (ВКПМ В-3491)
WO2008094065A1 (fr) MÉTHODE ET AGENT À BASE DE SOUCHES D'Enterococcus faecium M (VKPM B-3490) ET D'Enterococcus faecium M-3185 (VKPM B-3491) SERVANT AU TRAITEMENT D'HÉPATITES VIRALES
CN106619591B (zh) 奥昔卡因在制备药物中的用途及药物组合物
Lingappa et al. Herpes Zoster Infection: Effective Management Using Yoga Prana Vidya Healing Protocols
US20190388484A1 (en) Lactobacillus reuteri gmnl-263 for improving hypertension and its compositions thereof
US11617729B2 (en) Uses of guanidine hydrochloride as a drug for treating cancers/tumors
Ames Electromyography
RU2098106C1 (ru) Способ лечения гепатитов
WO2018093735A2 (fr) Méthode de traitement de l'hépatite c
RU2763024C1 (ru) Мефлохин и его комбинации для лечения и профилактики коронавирусной инфекции
Curran et al. Hepatic and renal failure associated with amiodarone infusion in a patient with hereditary fructose intolerance
KAMAL et al. COVID-19 IN A PACIENT WITH HIV INFECTION--A CASE REPORT.
Mete et al. Safety Evaluation and Tolerability Overview of Favipiravir in the Management of COVID-19: A Real-Life Experience from Turkey
CN106361737A (zh) 曲尼司特在制备治疗结核病的药物中的应用
Anur et al. CASE OF TREATMENT OF BB AND CCB POISONING WITH HIGH-DOSE INSULIN EUGLYCEMIC THERAPY (HIET)
JP2006213607A (ja) 尿酸値低下剤
JP2007522075A (ja) 肝不全の治癒並びに肝臓代謝の再生及び強化のためのエンテロコッカス・フェシウム（ＥｎｔｅｒｏｃｏｃｃｕｓＦａｅｃｉｕｍ）菌株の使用
Sabiescu et al. COVID-19 in a Pacient with HIV Inflection-A Case Study
Esenbuğa et al. Thyrotoxic Hypokalemic Periodic Paralysis: A Case Report

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07793990

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009132744

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07793990

Country of ref document: EP

Kind code of ref document: A1